HARMONY Work Packages 2 & 6 Leadership in action in London, during Workshop: Meaningful Outcomes for HMs

Today and tomorrow the Leadership of HARMONY Work Packages 2 & 6 are organizing a workshop on the definition of meaningful outcomes for hematological malignancies at HARMONY Partner Takeda in London, UK. With over 52 multidisciplinary professionals present, lively discussions on outcomes relevant to all stakeholders will take place. The objectives of the workshop are brainstorming, exchanging, and generating ideas to elaborate a list of outcomes relevant to all stakeholders. It also aims to create and group by HM a description of such outcomes and, in addition, to shortlist the standard core outcomes that are valid for all HMs. 

Read more >>

 

---

From left to right:

• Helene Chevrou-Severac, HARMONY Partner, WP6 Leader, Director HEOR in Medical Affairs, Celgene
• Renate Schulze-Rath, HARMONY Partner, WP2 Leader, Director, Oncology1/WHC, Bayer
• Jan Geissler, HARMONY Partner, WP6 Leader, Founder and CEO LeukaNET
• Lars Bullinger, HARMONY Partner, WP2 Leader, Professor in Personalized Medicine Charité (formerly working at Universitaet Ulm)
• Aliki Taylor, HARMONY Partner, WP2 Co-leader, Director Global Outcomes Research, Takeda
• Christina Donatti, HARMONY Partner, WP6 Co-leader, IMI Lead, Real World Evidence, EMEA Strategic Organisation, JPNV-JANSSEN

---

 

  

 

---

 

    

---

Receive the latest news. Click here to subscribe!